Live Breaking News & Updates on Anthera Pharmaceuticals Holding Kurs

Stay updated with breaking news from Anthera pharmaceuticals holding kurs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE) in Patients with Duchenne Muscular Dystrophy in Neurology

14.02.2024 - Results from 112 patients with DMD who completed the study confirm maintenance of efficacy and benefits in safety and tolerability of treatment with vamorolone over 48 weeks AGAMREE has shown safety benefits in patients switching from standard of . Seite 1 ....

Switzerland General , United Kingdom , European Union , Santhera Pharmaceuticals , Vamorolone Over , Boys With Duchenne Muscular , North Star Ambulatory Assessment , Santhera Pharmaceuticals Holding Chart , Anthera Pharmaceuticals Holding Kurs , Anthera Pharmaceuticals Holding Aktie ,

Santhera's AGAMREE (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy Seite 1

18.12.2023 - European Commission (EC) grants marketing authorization for AGAMREE for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and olderAGAMREE is the only approved medication in the European Union (EU) for treating DMD, and the . Seite 1 ....

Switzerland General , Elizabeth Vroom , Dario Eklund , World Duchenne Organization , European Commission , European Union , Drug Administration , Santhera Pharmaceuticals , European Medicines Agency , Duchenne Organization , World Duchenne , Santhera Pharmaceuticals Holding Chart , Anthera Pharmaceuticals Holding Kurs , Anthera Pharmaceuticals Holding Aktie ,